Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVERLY: bevacizumab + erlotinib vs erlotinib in EGFR-mutated advanced non-squamous NSCLC
2024-516843-15-00Phase 3Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing bevacizumab + erlotinib with erlotinib monotherapy (2 arms). Primary endpoints: Investigator-assessed progression-free survival (IA-PFS) and Blinded independent centrally reviewed progression-free survival (BICR-PFS). Planned start Nov 2024; status: authorised.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516843-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516843-15-00.